RxDoctor Payments Data

Michael Liu, MD

Neurology · Alton, ILNPI 1851402721

Payments from drug & device makers

$8,139in general payments, 2019–2025

Across 492 payments — averaging $16.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$949
  • AbbVie$894
  • Supernus Pharmaceuticals, Inc.$655
  • UCB, Inc.$650
  • Biogen$353
  • MDD US Operations, LLC$298
  • plus $4K from 54 others

What the payments were for

  • Speaking & faculty fees$661%
  • Food & beverage$8,05199%
  • Education$230%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis69$949
AbbVie(2 entities)52$894
Supernus Pharmaceuticals, Inc.44$655
UCB, Inc.40$650
Biogen30$353
MDD US Operations, LLC9$298
Sunovion Pharmaceuticals Inc.19$247
Bristol Myers Squibb16$238
Amgen10$225
Lilly USA, LLC11$222
Teva Pharmaceuticals USA, Inc.20$221
Eisai Inc.10$202
Genentech USA, Inc.9$157
Neurelis, Inc.8$156
Jazz Pharmaceuticals Inc.8$154
CSL Behring6$152
Pfizer9$150
Sumitomo Pharma America, Inc.7$141
Acorda Therapeutics, Inc8$123
Acadia Pharmaceuticals Inc8$121
Sanofi8$121
Johnson & Johnson6$108
SK Life Science, Inc.5$89
Neurocrine Biosciences, Inc.5$89
Adamas Pharmaceuticals, Inc.5$87
Vanda Pharmaceuticals Inc.4$86
Avanir Pharmaceuticals, Inc.5$78
Grifols USA, LLC4$76
AstraZeneca3$71
Resmed Corp1$66
Lundbeck LLC4$65
Ipsen Biopharmaceuticals, Inc4$60
GE HealthCare3$58
Xeris Pharmaceuticals, Inc.3$56
EMD Serono, Inc.3$53
Impel Pharmaceuticals Inc.2$50
Greenwich Biosciences, Inc.2$50
Abbott2$45
Biohaven Pharmaceutical Holding Company Ltd.2$41
Medtronic(2 entities)2$39
Argenx US, Inc.2$38
Sanofi-aventis U.S. LLC2$32
Novo Nordisk2$32
Upsher-smith Laboratories LLC2$30
Axsome Therapeutics, Inc.1$30
Boston Scientific2$29
Kyowa Kirin, Inc.2$26
Itamar Medical Inc1$23
Corium, LLC1$22
Amarin Pharma, Inc.1$21
Catalyst Pharmaceuticals, Inc.1$21
Fisher & Paykel Healthcare Inc1$20
Harmony Biosciences LLC1$18
Amneal Pharmaceuticals LLC1$16
TG Therapeutics, Inc.1$16
Life Molecular Imaging Ltd1$16
Inspire Medical Systems, Inc.1$15
Avadel CNS Pharmaceuticals, LLC1$14
Avion Pharmaceuticals1$12
Promius Pharma LLC1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,139 in reported general payments places this provider in the 70th percentile of 790 neurology providers in Illinois.

See all neurology providers in Illinois

Medicare billing

Part B allowed, 2024
$169,813
Medicare patients
647
Services billed
6,471

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab25$234,545
Rebif RebidoseInterferon Beta-1a/Albumin13$134,518
Teriflunomide17$76,759
CopaxoneGlatiramer Acetate11$62,044
UbrelvyUbrogepant22$32,163
QuliptaAtogepant22$24,256
Memantine Hcl338$12,811
Emgality SyringeGalcanezumab-Gnlm16$12,512
Aimovig AutoinjectorErenumab-Aooe12$11,765
Lacosamide54$7,655
FycompaPerampanel12$5,974
Levetiracetam151$4,020
Carbamazepine66$3,923
Dimethyl Fumarate17$2,954
Primidone73$2,369

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Copaxone$221$62,04411 claims
AbbVieUbrelvy, Qulipta$894$56,42044 claims
Eisai Inc.Fycompa$202$5,97412 claims
Upsher-smith Laboratories LLCTopiramate$30$2,236212 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$16$1,37516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 790 neurology providers in Illinois.

Other neurology in Alton

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →